Drug intelligence / Profile preview

KSP-0914

Development stage: Unknown
Lead developer: Kissei Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KSP-0914 is an orally bioavailable small molecule antagonist of the thyroid-stimulating hormone receptor (TSHR), currently under development by Kissei Pharmaceutical for the treatment of Graves' disease. In Graves' disease, autoantibodies (thyroid-stimulating immunoglobulins) bind to and activate the TSH receptor, leading to excessive production of thyroid hormones and hyperthyroidism. KSP-0914 is designed to block these autoantibodies from binding to and activating the receptor, thereby normalizing thyroid function. The compound has completed Phase 1 clinical trials, including dose-escalation studies in both Japanese and Caucasian healthy volunteers.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on KSP-0914.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSP-0914.

Explore the full profile